Compare
Outlook Therapeutics, Inc. vs Inhibrx Biosciences, Inc. vs Humacyte, Inc. vs Aligos Therapeutics, Inc.
| Latest fiscal year | Outlook Therapeutics, Inc. OTLK | Inhibrx Biosciences, Inc. INBX | Humacyte, Inc. HUMA | Aligos Therapeutics, Inc. ALGS |
|---|---|---|---|---|
| Year ended | 2025-09-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.41M | $1.30M | $2.04M | $2.19M |
| Revenue growth (YoY) | n/a | +550.0% | n/a | -39.5% |
| Gross margin | 4.0% | n/a | -376.1% (computed) | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$62.42M | -$140.06M | -$40.83M | -$24.19M |
| EPS (Diluted) | -$1.79 | -$9.04 | -$0.26 | -$2.45 |
| Operating cash flow | -$51.83M | -$129.79M | -$105.04M | -$82.50M |
| Free cash flow | n/a | -$129.82M | -$105.93M | n/a |
| Cash & equivalents | $8.08M | $124.22M | $50.50M | $18.30M |
| Total assets | $18.58M | $146.48M | $116.37M | $88.53M |
| Total liabilities | $50.77M | $138.49M | $113.26M | $34.99M |
| Shareholders' equity | -$32.19M | $7.99M | $3.11M | $53.55M |
| Return on year-end equity | n/a | n/m | n/m | -45.2% |
| Shares outstanding | 53.89M | 14.58M | 193.00M | 6.18M |
Revenue, most recent five fiscal years
| Fiscal year | Outlook Therapeutics, Inc. | Inhibrx Biosciences, Inc. | Humacyte, Inc. | Aligos Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $1.41M Ended 2025-09-30 | $1.30M Ended 2025-12-31 | $2.04M Ended 2025-12-31 | $2.19M Ended 2025-12-31 |
| 1 year earlier | n/a | $200.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $3.61M Ended 2024-12-31 |
| 2 years earlier | n/a | $1.80M Ended 2023-12-31 | n/a | $6.19M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | n/a | $0 Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $0 Ended 2021-12-31 |